These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15658862)

  • 1. Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
    Berger Y; Dehmlow H; Blum-Kaelin D; Kitas EA; Löffler BM; Aebi JD; Juillerat-Jeanneret L
    J Med Chem; 2005 Jan; 48(2):483-98. PubMed ID: 15658862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
    Porter KE; Dickinson T; London NJ
    J Vasc Surg; 2001 Sep; 34(3):548-54. PubMed ID: 11533610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
    J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
    Smollich M; Götte M; Yip GW; Yong ES; Kersting C; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2007 Dec; 106(3):361-9. PubMed ID: 17295044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
    Fink CA; Moskal M; Firooznia F; Hoyer D; Symonsbergen D; Wei D; Qiao Y; Savage P; Beil ME; Trapani AJ; Jeng AY
    Bioorg Med Chem Lett; 2000 Sep; 10(17):2037-9. PubMed ID: 10987444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells.
    Rayhman O; Klipper E; Muller L; Davidson B; Reich R; Meidan R
    Cancer Res; 2008 Nov; 68(22):9265-73. PubMed ID: 19010899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
    Inguimbert N; Poras H; Teffo F; Beslot F; Selkti M; Tomas A; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2001-5. PubMed ID: 12113828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of endothelin-converting enzyme activities in ARPE-19 cells, a human retinal pigmented epithelial cell line.
    Dibas A; Prasanna G; Yorio T
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):196-204. PubMed ID: 15969636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.
    Firooznia F; Gude C; Chan K; Tan J; Fink CA; Savage P; Beil ME; Bruseo CW; Trapani AJ; Jeng AY
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3059-62. PubMed ID: 12372501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
    Jeng AY; Mulder P; Kwan AL; Battistini B
    Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ECE-1 influences prostate cancer cell invasion via ET-1-mediated FAK phosphorylation and ET-1-independent mechanisms.
    Whyteside AR; Hinsley EE; Lambert LA; McDermott PJ; Turner AJ
    Can J Physiol Pharmacol; 2010 Aug; 88(8):850-4. PubMed ID: 20725143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endothelin axis: a novel target for pharmacotherapy of female malignancies.
    Smollich M; Wülfing P
    Curr Vasc Pharmacol; 2007 Jul; 5(3):239-48. PubMed ID: 17627567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
    Inguimbert N; Poras H; Dhotel H; Beslot F; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    J Pept Res; 2004 Feb; 63(2):99-107. PubMed ID: 15009531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
    Usmani BA; Harden B; Maitland NJ; Turner AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-converting enzyme inhibitors: current status and perspectives.
    Löffler BM
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.